AU2018250609B2 - Prodrugs of 2-PMPA for healthy tissue protection during PSMA-targeted cancer imaging or radiotherapy - Google Patents

Prodrugs of 2-PMPA for healthy tissue protection during PSMA-targeted cancer imaging or radiotherapy Download PDF

Info

Publication number
AU2018250609B2
AU2018250609B2 AU2018250609A AU2018250609A AU2018250609B2 AU 2018250609 B2 AU2018250609 B2 AU 2018250609B2 AU 2018250609 A AU2018250609 A AU 2018250609A AU 2018250609 A AU2018250609 A AU 2018250609A AU 2018250609 B2 AU2018250609 B2 AU 2018250609B2
Authority
AU
Australia
Prior art keywords
pmpa
psma
kidney
poc
tris
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018250609A
Other languages
English (en)
Other versions
AU2018250609A1 (en
Inventor
Clemens KRATOCHWIL
Michael NEDELCOVYCH
Rana RAIS
Barbara Slusher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adarga LLC
Johns Hopkins University
Original Assignee
Adarga LLC
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adarga LLC, Johns Hopkins University filed Critical Adarga LLC
Publication of AU2018250609A1 publication Critical patent/AU2018250609A1/en
Assigned to THE JOHNS HOPKINS UNIVERSITY, ADARGA, LLC reassignment THE JOHNS HOPKINS UNIVERSITY Amend patent request/document other than specification (104) Assignors: Adraga, LLC, THE JOHNS HOPKINS UNIVERSITY
Application granted granted Critical
Publication of AU2018250609B2 publication Critical patent/AU2018250609B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0489—Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2018250609A 2017-04-11 2018-04-11 Prodrugs of 2-PMPA for healthy tissue protection during PSMA-targeted cancer imaging or radiotherapy Active AU2018250609B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762484219P 2017-04-11 2017-04-11
US62/484,219 2017-04-11
PCT/US2018/027106 WO2018191376A2 (en) 2017-04-11 2018-04-11 Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy

Publications (2)

Publication Number Publication Date
AU2018250609A1 AU2018250609A1 (en) 2019-10-31
AU2018250609B2 true AU2018250609B2 (en) 2024-05-09

Family

ID=63792979

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018250609A Active AU2018250609B2 (en) 2017-04-11 2018-04-11 Prodrugs of 2-PMPA for healthy tissue protection during PSMA-targeted cancer imaging or radiotherapy

Country Status (10)

Country Link
US (1) US12508271B2 (enExample)
EP (1) EP3609544B1 (enExample)
JP (3) JP2020530007A (enExample)
KR (1) KR102686172B1 (enExample)
CN (1) CN111801121B (enExample)
AU (1) AU2018250609B2 (enExample)
ES (1) ES3021195T3 (enExample)
IL (1) IL269969B2 (enExample)
SG (1) SG11201909513QA (enExample)
WO (1) WO2018191376A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
AU2014336638C1 (en) 2013-10-18 2020-09-17 Novartis Ag Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
WO2015073678A1 (en) 2013-11-14 2015-05-21 Endocyte, Inc. Compounds for positron emission tomography
MX2020010813A (es) 2018-04-17 2021-01-08 Endocyte Inc Metodos de tratamiento de cancer.
JP7429688B2 (ja) * 2018-09-21 2024-02-08 エンドサイト・インコーポレイテッド シールド剤およびそれらの使用
EP3972627A4 (en) 2019-05-20 2023-06-21 Endocyte, Inc. Methods for preparing psma conjugates
WO2021202376A1 (en) * 2020-03-30 2021-10-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method for blocking uptake of prostate-specific membrane antigen (psma)-targeted radionuclides by exocrine organs
US20230165980A1 (en) * 2020-04-29 2023-06-01 Novartis Ag Methods for radiolabeling psma binding ligands and their kits
IL297323A (en) * 2020-04-29 2022-12-01 Novartis Ag Methods for radiological labeling of psma-binding ligands and their kits
AU2021352915A1 (en) * 2020-10-01 2023-06-08 Cornell University Methods and compositions for increasing uptake, internalization, and/or retention of small molecule ligands
WO2022106629A1 (en) 2020-11-19 2022-05-27 Novartis Ag Synthesis of prostate specific membrane antigen (psma) ligands
CN113354709B (zh) * 2021-06-03 2023-06-09 江苏华益科技有限公司 一种转移性前列腺癌靶向性药物前体的固相合成方法
EP4536278A4 (en) 2022-06-07 2026-08-12 Actinium Pharmaceuticals Inc CHELETARIANS AND BIFUNCTIONAL CONJUGATES
WO2023239903A1 (en) * 2022-06-09 2023-12-14 Case Western Reserve University Compositions and methods for preventing retention of psma-targeted therapy
AU2024317528A1 (en) 2023-07-31 2026-03-05 Curium Us Llc [177 lu] lutetium-psma it composition and dosimetry, kit, method of making, and method of using thereof
WO2025167998A1 (zh) * 2024-02-06 2025-08-14 北京昌平实验室 膦酸酯骨架的psma靶向偶联物
WO2026120497A1 (en) 2024-12-05 2026-06-11 Novartis Ag Stable radionuclide complex solutions

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046294A2 (en) * 2007-10-03 2009-04-09 Cornell University Treatment of proliferative disorders using antibodies to psma
WO2016022827A1 (en) * 2014-08-06 2016-02-11 The Johns Hopkins University Prodrugs of prostate specific membrane antigen (psma) inhibitor
US20160067361A1 (en) * 2014-09-08 2016-03-10 Molecular Insight Pharmaceuticals, Inc. Organ protection in psma-targeted radionuclide therapy of prostate cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10172873B2 (en) * 2014-08-06 2019-01-08 The Johns Hopkins University Methods for treating inflammatory bowel disease using prostate specific membrane antigen (PSMA) inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009046294A2 (en) * 2007-10-03 2009-04-09 Cornell University Treatment of proliferative disorders using antibodies to psma
WO2016022827A1 (en) * 2014-08-06 2016-02-11 The Johns Hopkins University Prodrugs of prostate specific membrane antigen (psma) inhibitor
US20160067361A1 (en) * 2014-09-08 2016-03-10 Molecular Insight Pharmaceuticals, Inc. Organ protection in psma-targeted radionuclide therapy of prostate cancer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHATALIC KRISTELL L S ET AL: THERANOSTICS, IVYSPRING INTERNATIONAL PUBLISHER, AU, vol. 6, no. 6, 1 January 2016 (2016-01-01), pages 849 - 861, XP009504265, ISSN: 1838-7640, DOI: 10.7150/THNO.14744 *
KRATOCHWIL CLEMENS ET AL:THE JOURNAL OF NUCLEAR MEDICINE, SOCIETY OF NUCLEAR MEDICINE, US, vol. 56, no. 2, 31 January 2015 (2015-01-31), pages 293 - 298, XP009504269, ISSN: 0161-5505, DOI: 10.2967/JNUMED.114.147181 *

Also Published As

Publication number Publication date
JP2020530007A (ja) 2020-10-15
JP2025028897A (ja) 2025-03-05
EP3609544C0 (en) 2025-04-09
EP3609544A2 (en) 2020-02-19
CA3059741A1 (en) 2018-10-18
JP2023093545A (ja) 2023-07-04
ES3021195T3 (en) 2025-05-26
WO2018191376A3 (en) 2018-12-27
KR102686172B1 (ko) 2024-07-17
WO2018191376A2 (en) 2018-10-18
KR20200059187A (ko) 2020-05-28
EP3609544B1 (en) 2025-04-09
CN111801121B (zh) 2023-12-01
IL269969B2 (en) 2023-04-01
US12508271B2 (en) 2025-12-30
AU2018250609A1 (en) 2019-10-31
SG11201909513QA (en) 2019-11-28
IL269969A (en) 2022-12-01
EP3609544A4 (en) 2020-12-23
US20200069706A1 (en) 2020-03-05
CN111801121A (zh) 2020-10-20

Similar Documents

Publication Publication Date Title
EP3609544B1 (en) Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy
US20230147035A1 (en) Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
ES2877572T3 (es) Agentes de alta afinidad dirigidos a antígenos de membrana específicos de próstata para la endorradioterapia del cáncer de próstata
US10736974B2 (en) Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy
CN109476655B (zh) 靶向碳酸酐酶ix的核成像剂和放射治疗剂及其用途
JP2020522506A5 (enExample)
WO2020061293A1 (en) Shielding agents and their use
CA3059741C (en) Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy
US20210308286A1 (en) Long-circulating psma-targeted phototheranostic agent
HK40037500A (en) Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy
HK40037500B (en) Prodrugs of 2-pmpa for healthy tissue protection during psma-targeted cancer imaging or radiotherapy
WO2025042989A1 (en) Psma-based albumin binding agents for targeted radionuclide therapy of prostate cancer
HK1259764B (en) Prostate-specific membrane antigen targeted high-affinity agents for endoradiotherapy of prostate cancer
HK40006359B (en) Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase ix and uses thereof
HK40006359A (en) Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase ix and uses thereof

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: ADARGA, LLC

Free format text: FORMER NAME(S): THE JOHNS HOPKINS UNIVERSITY; ADRAGA, LLC

Owner name: THE JOHNS HOPKINS UNIVERSITY

Free format text: FORMER NAME(S): THE JOHNS HOPKINS UNIVERSITY; ADRAGA, LLC

FGA Letters patent sealed or granted (standard patent)